|
1
|
Goodenberger ML and Jenkins RB: Genetics
of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sathornsumetee S, Reardon DA, Desjardins
A, Quinn JA, Vredenburgh JJ and Rich JN: Molecularly targeted
therapy for malignant glioma. Cancer. 110:13–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Watts C, Price SJ and Santarius T: Current
concepts in the surgical management of glioma patients. Clin Oncol
(R Coll Radiol). 26:385–394. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marumoto T and Saya H: Molecular biology
of glioma. Adv Exp Med Biol. 746:2–11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guo N, Liu F, Yang L, Huang J, Ding X and
Sun C: Chemokine receptor 7 enhances cell chemotaxis and migration
of metastatic squamous cell carcinoma of head and neck through
activation of matrix metalloproteinase-9. Oncol Rep. 32:794–800.
2014.PubMed/NCBI
|
|
6
|
van der Vorst EP, Döring Y and Weber C:
Chemokines. Arterioscler Thromb Vasc Biol. 35:e52–e56. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ding J and Tredget EE: The role of
chemokines in fibrotic wound healing. Adv Wound Care (New
Rochelle). 4:673–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Duchene J and von Hundelshausen P:
Platelet-derived chemokines in atherosclerosis. Hamostaseologie.
35:137–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marra F and Tacke F: Roles for chemokines
in liver disease. Gastroenterology. 147:577–594.e1. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sarvaiya PJ, Guo D, Ulasov I, Gabikian P
and Lesniak MS: Chemokines in tumor progression and metastasis.
Oncotarget. 4:2171–2185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Łukaszewicz-Zając M, Mroczko B and
Szmitkowski M: Chemokines and their receptors in esophageal
cancer-the systematic review and future perspectives. Tumour Biol.
36:5707–5714. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chow MT and Luster AD: Chemokines in
cancer. Cancer Immunol Res. 2:1125–1131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z, Sun J, Feng Y, Tian X, Wang B and
Zhou Y: Oncogenic roles and drug target of CXCR4/CXCL12 axis in
lung cancer and cancer stem cell. Tumour Biol. 37:8515–8528. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rowland KJ, Diaz-Miron J, Guo J, Erwin CR,
Mei J, Worthen GS and Warner BW: CXCL5 is required for
angiogenesis, but not structural adaptation after small bowel
resection. J Pediatr Surg. 49:976–980. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Madalli S, Beyrau M, Whiteford J, Duchene
J, Nandhra I Singh, Patel NS, Motwani MP, Gilroy DW, Thiemermann C,
Nourshargh S, et al: Sex-specific regulation of chemokine Cxcl5/6
controls neutrophil recruitment and tissue injury in acute
inflammatory states. Biol Sex Differ. 6:272015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang H, Ning H, Banie L, Wang G, Lin G,
Lue TF and Lin CS: Adipose tissue-derived stem cells secrete CXCL5
cytokine with chemoattractant and angiogenic properties. Biochem
Biophys Res Commun. 402:560–564. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao Y, Guan Z, Chen J, Xie H, Yang Z, Fan
J, Wang X and Li L: CXCL5/CXCR2 axis promotes bladder cancer cell
migration and invasion by activating PI3K/AKT-induced upregulation
of MMP2/MMP9. Int J Oncol. 47:690–700. 2015.PubMed/NCBI
|
|
18
|
Xia J, Xu X, Huang P, He M and Wang X: The
potential of CXCL5 as a target for liver cancer - what do we know
so far? Expert Opin Ther Targets. 19:141–146. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu X, Qiao Y, Liu W, Wang W, Shen H, Lu
Y, Hao G, Zheng J and Tian Y: CXCL5 is a potential diagnostic and
prognostic marker for bladder cancer patients. Tumour Biol.
37:4569–4577. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW,
Wang Z, Fan J, Dai Z and Zhou J: CXCR2/CXCL5 axis contributes to
epithelial-mesenchymal transition of HCC cells through activating
PI3K/Akt/GSK-3β/Snail signaling. Cancer Lett. 358:124–135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park JY, Park KH, Bang S, Kim MH, Lee JE,
Gang J, Koh SS and Song SY: CXCL5 overexpression is associated with
late stage gastric cancer. J Cancer Res Clin Oncol. 133:835–840.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dimberg J, Dienus O, Löfgren S, Hugander A
and Wågsäter D: Expression and gene polymorphisms of the chemokine
CXCL5 in colorectal cancer patients. Int J Oncol. 31:97–102.
2007.PubMed/NCBI
|
|
24
|
Miyazaki H, Patel V, Wang H, Edmunds RK,
Gutkind JS and Yeudall WA: Down-regulation of CXCL5 inhibits
squamous carcinogenesis. Cancer Res. 66:4279–4284. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu X, Tian Y, Lu N, Gin T, Cheng CH and
Chan MT: Stat3 inhibition attenuates mechanical allodynia through
transcriptional regulation of chemokine expression in spinal
astrocytes. PLoS One. 8:e758042013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Disteldorf EM, Krebs CF, Paust HJ, Turner
JE, Nouailles G, Tittel A, Meyer-Schwesinger C, Stege G, Brix S,
Velden J, et al: CXCL5 drives neutrophil recruitment in
TH17-mediated GN. J Am Soc Nephrol. 26:55–66. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nedeau AE, Bauer RJ, Gallagher K, Chen H,
Liu ZJ and Velazquez OC: A CXCL5- and bFGF-dependent effect of
PDGF-B-activated fibroblasts in promoting trafficking and
differentiation of bone marrow-derived mesenchymal stem cells. Exp
Cell Res. 314:2176–2186. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao L: Hirudin inhibits cell growth via
ERK/MAPK signaling in human glioma. Int J Clin Exp Med.
8:20983–20987. 2015.PubMed/NCBI
|
|
29
|
Yan Y and Jiang Y: RACK1 affects glioma
cell growth and differentiation through the CNTN2-mediated
RTK/Ras/MAPK pathway. Int J Mol Med. 37:251–257. 2016.PubMed/NCBI
|
|
30
|
Lien LM, Wang MJ, Chen RJ, Chiu HC, Wu JL,
Shen MY, Chou DS, Sheu JR, Lin KH and Lu WJ: Nobiletin, a
polymethoxylated flavone, inhibits glioma cell growth and migration
via arresting cell cycle and suppressing MAPK and Akt pathways.
Phytother Res. 30:214–221. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Merabova N, Kaminski R, Krynska B, Amini
S, Khalili K and Darbinyan A: JCV agnoprotein-induced reduction in
CXCL5/LIX secretion by oligodendrocytes is associated with
activation of apoptotic signaling in neurons. J Cell Physiol.
227:3119–3127. 2012. View Article : Google Scholar : PubMed/NCBI
|
